CRBP
CRBP clinical trials: Corbus Pharmaceuticals Holdings, Inc.
Every trial on ClinicalTrials.gov where Corbus Pharmaceuticals Holdings, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 10
- As lead sponsor
- 1
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
CRBP on the catalyst calendar · CRBP registry changes
- Primary completion Jan 30, 2026ActualPhase 1/Phase 2NCT06603844First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.Corbus Pharmaceuticals Inc. · Solid TumorCompletedCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2026ActualPhase 1NCT07310901A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With ObesityCorbus Pharmaceuticals Inc. · Obese But Otherwise Healthy ParticipantsCompletedCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 3NCT07768189A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaCorbus Pharmaceuticals Inc. · Oropharyngeal Carcinoma (OPC)RecruitingCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2027Sponsor estimatePhase 1/Phase 2NCT06265727A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsCorbus Pharmaceuticals Inc. · Solid Tumor, AdultRecruitingCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2017ActualPhase 2NCT02466243Safety, Tolerability, and Efficacy of JBT-101 in Subjects With DermatomyositisCorbus Pharmaceuticals Inc. · DermatomyositisTerminatedCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2020ActualPhase 2NCT03451045Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCorbus Pharmaceuticals Inc. · Cystic FibrosisCompletedCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2021ActualPhase 3NCT03813160Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisCorbus Pharmaceuticals Inc. · DermatomyositisCompletedCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 27, 2020ActualPhase 3NCT03398837Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic SclerosisCorbus Pharmaceuticals Inc. · Diffuse Cutaneous Systemic SclerosisTerminatedCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2016ActualPhase 2NCT02465437Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic SclerosisCorbus Pharmaceuticals Inc. · Diffuse Cutaneous Systemic SclerosisTerminatedCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2016ActualPhase 2NCT02465450Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic FibrosisCorbus Pharmaceuticals Inc. · Cystic FibrosisCompletedCRBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 28, 2021ActualPhase 2NCT03093402JBT-101 in Systemic Lupus Erythematosus (SLE)National Institute of Allergy and Infectious Diseases (NIAID) · Systemic Lupus ErythematosusCompletedCRBPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner